MedTrace Logo

Surgical Nivolumab And Ipilimumab For Recurrent GBM

NCT04606316 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-02-17

No results posted yet for this study

Summary

This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.

The names of the study drugs involved in this study are:

* Nivolumab
* Ipilimumab
* Placebo (IV solution with no medicine)
* Zr-89 Crefmirlimab berdoxam (optional sub-study)

Conditions

Interventions

DRUG

Nivolumab-Placebo

Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

DRUG

Nivolumab

Given as intravenous (IV) infusion into a vein.

DRUG

Ipilimumab-Placebo

Intravenous (IV) solution that has no therapeutic effect, used as a control in testing investigational drug. One dose is received prior to surgery.

DRUG

Ipilimumab

Given as intravenous (IV) infusion into a vein.

PROCEDURE

Surgery

Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.

Sponsors & Collaborators

Principal Investigators

  • Patrick Y Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2026-12-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606316 on ClinicalTrials.gov